Last updated: February 20, 2026
What is the drug associated with NDC 70710-1364?
NDC 70710-1364 refers to Rimegepant, marketed under the brand name Nurtec ODT. It is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA in 2020 for acute treatment of migraine and prophylaxis.
Market Overview
Indications and Approved Uses
- Acute treatment of migraine in adults.
- Prevention of migraine in adults.
Market Size
- U.S. migraine market estimated at approximately $4 billion in 2022.
- Rimegepant accounted for 10-15% of the migraine treatment market since launch.
Competition
- Main competitors include ubrogepant (Rupacta, settled brand), acetaminophen, NSAIDs, and triptans.
- Erenumab, galcanezumab, and fremanezumab provide preventive therapy options, often used with or instead of Rimegepant.
Sales Dynamics
- Launch period showed rapid adoption, driven by favorable efficacy and safety profile.
- Sales growth slowed in 2022 owing to market saturation and competitive offerings.
Patent and Exclusivity
- Patent expiration is projected for 2030.
- Orphan drug designation granted, granting 7 years of market exclusivity from approval.
Price Point Analysis
Current Pricing
- Retail list price: approximately $850 per 8-dose pack (30 mg tablets).
- Patient out-of-pocket costs: varies based on insurance, often between $20 and $50 with copay assistance.
Wholesale Acquisition Cost (WAC)
- The WAC is approximately $600 per package.
- No significant discounts are currently publicly reported.
REimbursement
- Medicare Part D: coverage depends on formulary inclusion.
- Commercial insurance: generally covers with prior authorization.
- Patient assistance programs mitigate out-of-pocket costs.
Price Projections
Short-term (1-2 years)
- Price stability expected due to limited competition and ongoing demand.
- Generics unlikely before patent expiry (2030).
- Cost may increase marginally, influenced by inflation and supply chain factors.
Medium to Long-term (3-5 years)
- Potential price decline if biosimilar or generic Rimegepant enters the market, possibly reducing list price by 30-50%.
- If new formulations or combination therapies are approved, price adjustments could occur.
Impact of Market Dynamics
| Factor |
Effect on Price |
Timeline |
| Patent expiration |
Pricing decline |
2030+ |
| New competitors |
Pricing pressure |
2025-2028 |
| Healthcare policy changes |
Reimbursement shifts |
2023-2025 |
Demand-Side Factors
- Increasing prevalence of migraine (~15% of global population).
- Physician preference for CGRP antagonists over older therapies.
- Insurance coverage expansion.
Summary of Market Trends
- The drug retains a dominant position within the acute migraine treatment segment.
- Pricing maintained due to limited competition.
- Entry of generics or biosimilars anticipated post-2030 will likely threaten current pricing, leading to substantial discounts.
Key Takeaways
- NDC 70710-1364 (Rimegepant) is a key player in migraine treatment, with current premium pricing sustained by patent exclusivity and brand recognition.
- Wholesale acquisition costs remain stable with minimal discounts; patient costs depend heavily on insurance coverage.
- Market entry of generics, expected after 2030, will pose a challenge to current pricing.
- Broader market trends favor increased prescribing of CGRP antagonists, supporting demand but also risking future price reductions.
FAQs
1. When will generic Rimegepant be available?
Post-patent expiration, expected around 2030.
2. How does Rimegepant compare price-wise to triptans?
It is significantly more expensive—$850 per pack versus ~$50 for many triptans—driven by different delivery methods and patent protections.
3. What factors could influence its market share?
Emergence of biosimilars, changes in insurance coverage, physician prescribing habits, and new therapeutic options.
4. Will price reductions occur due to competition?
Yes, especially after patent expiry, with potential discounts of 30-50% upon generic entry.
5. How does insurance impact patient costs?
Insurance coverage can reduce out-of-pocket costs from hundreds to tens of dollars, contingent on formulary status and copay assistance programs.
References
- IQVIA. (2022). Migraine Market Report.
- FDA. (2020). Rimegepant (Nurtec ODT) Approval Documentation.
- MarketWatch. (2023). Migraine Drugs Market Size and Trends.
- Centers for Medicare & Medicaid Services. (2023). Part D Coverage Policies.
- Statista. (2022). Global Migraine Prevalence and Treatments.
